Pulmonary toxicty is a life threatening condition that occurs in a percentage of all Amiodarone users. It is difficult to diagnose and is often mistaken for heart failure. Any patients on Amiodarone who suffer from bronchospasm, excessive coughing, dyspnea, or respiratory failure should contact a doctor immediately. In early 2004 the FDA required Wyeth, a manufacturer of Amiodarone, to produce a package insert to be provided with all prescriptions detailing the serious side effects of this drug. To date, the insert has not been completed.